SynthesisFrontiers in oncology2019
Diagnostic Value of Concentration of Circulating Cell-Free DNA in Breast Cancer: A Meta-Analysis.
Synthesis in Frontiers in oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Diagnostic Clinical Trials in Breast Cancer Brain Metastases: Barriers and Innovations.Clinical breast cancer · 2019Pooled it
- Circulating Cell-Free DNA as an Epigenetic Biomarker for Early Diabetic Retinopathy: A Narrative Review.Diagnostics (Basel, Switzerland) · 2025Review
- Molecular characterization of cell decay in inflammation and topological assignment of released cfDNA for integrative laboratory and radiological outcome assessment.Frontiers in cellular and infection microbiology · 2025Article
- Extracted Plasma Cell-Free DNA Concentrations Are Elevated in Colic Patients with Systemic Inflammation.Veterinary sciences · 2024Article
- DNA Hyperstructure.ACS omega · 2024Article
- Circulating tumor DNA: from discovery to clinical application in breast cancer.Frontiers in immunology · 2024Review
- Diagnostic value of combined detection of plasma cfDNA concentration and integrity in NSCLC.Lung cancer management · 2024Article
- Efficacy of cell-free DNA as a diagnostic biomarker in breast cancer patients.Scientific reports · 2023Article
- Estimation of ALU Repetitive Elements in Plasma as a Cost-Effective Liquid Biopsy Tool for Disease Prognosis in Breast Cancer.Cancers · 2023Article
- The Clinical Utility of Droplet Digital PCR for Profiling Circulating Tumor DNA in Breast Cancer Patients.Diagnostics (Basel, Switzerland) · 2022Review
- Circulating Cell Free DNA and DNA Integrity Index as Discriminating Tools between Breast Cancer and Benign Breast Disease.Asian Pacific journal of cancer prevention : APJCP · 2022Article
- Article
- The breast is yet to come: current and future utility of circulating tumour DNA in breast cancer.British journal of cancer · 2021Review
- Circulating Cell-Free DNA in Breast Cancer: Searching for Hidden Information towards Precision Medicine.Cancers · 2021Review
- Impact of Preanalytical and Analytical Methods on Cell-Free DNA Diagnostics.Frontiers in cell and developmental biology · 2021Article
- Can Circulating Cell-Free DNA or Circulating Tumor DNA Be a Promising Marker in Ovarian Cancer?Journal of oncology · 2021Review
- Plasma Level of MMP-10 May Be a Prognostic Marker in Early Stages of Breast Cancer.Journal of clinical medicine · 2020Article
- Utility of plasma cell-free DNA in metastatic castration-resistant prostate cancer.IJU case reports · 2020Article
- Cell free DNA as a diagnostic and prognostic marker for cardiovascular diseases.Clinica chimica acta; international journal of clinical chemistry · 2020Review
- The paradox of cancer genes in non-malignant conditions: implications for precision medicine.Genome medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The diagnostic value of the concentration of circulating cell-free DNA (cfDNA) for breast cancer has generated inconsistent results. The aim of this study was to evaluate the first diagnostic value of the concentration of cfDNA for breast cancer by meta-analysis. Studies were retrieved by searching PubMed, Cochrane Library, and Web of Science before June 2018. Sensitivity, specificity, diagnostic odds ratio (DOR), the summary receiver operating characteristic (SROC) curve, and the area under curve (AUC) were used to summarize overall diagnostic performance. The random-effects model was used to calculate the pooled statistics. Subgroup analysis and meta-regression analysis were carried out to detect the source of heterogeneity. A total of 13 studies were identified with 1,087 breast cancer patients and 720 healthy controls. Overall, the pooled sensitivity and specificity of concentration of cfDNA for breast cancer were 87% (95% CI, 73-94%) and 87% (95% CI, 79-93%), respectively. The pooled DOR was 32.93 (95% CI, 13.52-80.19) and the SROC curve revealed an AUC of 0.93 (95% CI, 0.91-0.95). Meta-regression analysis showed that no covariate had a significant correlation with relative DOR (RDOR). Publication bias was not detected in this meta-analysis. This meta-analysis indicates that the concentration of cfDNA has potential first diagnostic value for breast cancer and plasma may be a better source of cfDNA for detection of breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.